SecBot SecBot
8-K ·Filed Jun 16, 2026

PTCT

PTC THERAPEUTICS, INC.
NEUTRAL
Impact 5/10
Horizonweeks Processed5mo ago SEC0001104659-26-074292
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

The refinancing extends debt maturity by five years at zero interest cost, improving the balance sheet profile. However, the conversion feature introduces potential dilution at a 40% premium. Monitor for any accelerated share repurchases or additional 2026 note buybacks that could reduce the net cash position. The convertible arbitrage unwind by selling holders may create temporary buying pressure in the stock.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$73.27
T+0 close · Jun 16, 2026 · via day close
Latest settled
−8.05%
T+60 · $67.37
Vs SPY
−9.05%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 16 $73.27entry
  2. T+1 · 5mo ago +7.18%α +8.43% · $78.53
  3. T+5 · 5mo ago +12.09%α +14.32% · $82.13
  4. T+20 · 4mo ago +6.54%α +6.34% · $78.06
  5. T+60 · 2mo ago −8.05%α −9.05% · $67.37
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PTC Therapeutics priced $500M of 0% convertible senior notes due 2031 (plus a $50M greenshoe) to refinance its 1.5% 2026 notes. The company will use ~$328.8M of proceeds to repurchase $222M principal of the 2026 notes at a premium, extending maturities by five years at zero interest cost. The conversion price of $107.48 represents a 40% premium over the $76.77 closing price, limiting near-term dilution.

Key Facts

  • $500M aggregate principal of 0% convertible senior notes due 2031 priced on June 15, 2026
  • Initial purchasers granted a 13-day option for an additional $50M in notes
  • Net proceeds estimated at ~$486.8M (or ~$535.5M if greenshoe fully exercised)
  • ~$328.8M of net proceeds used to repurchase $222M principal of 1.5% 2026 notes via privately negotiated transactions
  • Conversion price of ~$107.48 per share, a 40% premium over the $76.77 closing price on June 15, 2026
  • Notes mature June 15, 2031; no interest; PTC cannot redeem before June 20, 2029
  • Remaining proceeds for general corporate purposes, including additional 2026 note repurchases

Financial Impact

Refinancing $222M of 1.5% 2026 notes with $500M of 0% 2031 notes; net proceeds after repurchase ~$158M for general corporate purposes. Interest savings of ~$3.3M/year on the repurchased portion.

debtinterest expensedilution

Risk Factors

  • Potential dilution if notes convert; full conversion would add ~4.65M shares at the initial conversion rate
  • Remaining 2026 notes not repurchased still mature in 2026, requiring cash or refinancing
  • Proceeds used for general corporate purposes may not generate sufficient returns to offset dilution

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-074292
Document: tm2618041d1_ex99-1.htm0001104659-26-074292
Document: 0001104659-26-074292-index-headers.html0001104659-26-074292
Document: 0001104659-26-074292-index.html0001104659-26-074292
Document: 0001104659-26-074292.txt0001104659-26-074292

Track record

29 reports on PTCT

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +19.01% at T+60 after the Apr 28, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.09 Now $60.97 −1.80% settles Nov 17
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $62.10 Now $60.97 −1.82% settles Nov 17
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $63.45 Now $60.97 −3.91% settles Nov 17
  4. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $64.14 to $64.91 Now $60.97 −4.94% ▲ +1.20% −0.12% vs SPY
  5. Nov 3, 202613d ago 8-K Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
  7. Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $68.12 to $68.97 Now $60.97 +10.50% ▼ −1.25% +0.40% vs SPY
  8. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $59.97 to $60.88 Now $60.97 +1.67% ▲ +1.52% +2.00% vs SPY
  9. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $63.02 to $64.46 Now $60.97 −3.25% ▲ +2.29% +2.67% vs SPY
  10. Oct 16, 20264w ago Insider Cluster Neutral 3/10 Entry $61.53 to $62.92 Now $60.97 −0.91% ▲ +2.26% +1.92% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 16, 2026